Italy· 048818025
ZEPOSIA*28 cps 0,92 mg
A ozanimod product containing ozanimod, registered in Italy by BRISTOL M.SQUIBB PHARMA EEIG, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Ozanimod is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AE02 (ozanimod), each read from that country’s own register.
- This record: Italy
- 8 of them publish a price we can compare per daily dose
Ozanimod · ATC L04AE02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ozanimod costs, country by country.
Normalised to the WHO defined daily dose (0.92 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ozanimod · price per daily dose (0.92 mg)
USD · FX 28 Sept 2026
- CH Switzerland$85.78
The record
At a glance
- Active substance
- Ozanimod
- Manufacturer
- BRISTOL M.SQUIBB PHARMA EEIG
- Country
- Italy (IT)
- ATC code
- L04AE02
- ATC class
- Ozanimod
- Defined daily dose
- 0.92 mg, O
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic048818025ZEPOSIA*28 cps 0,92 mgEUR 1878.92
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
852 interactions on record for ozanimod.
Graded by severity as the source publishes them — 578 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ozanimod · interactions on record
852 records
- 578 severe
- 271 moderate
- 3 minor
Most severe, free to view
- FamotidineA02BA03severe
- PapaverineA03AD01severe
- IsomethepteneA03AX10severe
- CisaprideA03FA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ozanimod in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomZeposia 0.23mg capsulesBristol-Myers Squibb Pharmaceuticals Ltd
- SwitzerlandZeposia 0.23 mg, HartkapselnBristol-Myers Squibb SA
- CzechiaZEPOSIABristol-Myers Squibb Pharma EEIG, Dublin
- NorwayZeposiaBristol-Myers Squibb Pharma EEIG (1)
- NetherlandsZeposia 0,23 mg capsule, hardBristol-Myers Squibb Pharma EEIG
- IcelandZeposiaBristol-Myers Squibb Pharma EEIG*
- BelgiumZeposia 0.23 mg - 0.46 mgBristol-Myers Squibb Pharma
- CanadaZEPOSIABRISTOL-MYERS SQUIBB CANADA
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zeposia
- Liechtenstein · Zeposia
- Norway · Zeposia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bd3a9961-f3a3-45f3-b2b1-9325adc2a4ef GET /v1/drugs/bd3a9961-f3a3-45f3-b2b1-9325adc2a4ef?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 1878.92,
"source": "aifa",
"currency": "EUR",
"strength": "OZANIMOD 0,92MG 28 UNITA' USO ORALE",
"substance": "Ozanimod",
"equivalence_group": "LPQ",
"transparency_flag": null
}See everything about ozanimod.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.